Project Grant R01EY037214
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded the Whitehead Institute for Biomedical Research a Project Grant of $173,016 under the Vision Research program (CFDA 93.867) to conduct systematic identification and mechanistic characterization of novel oxidative protective genes to prevent retinal pigment epithelium (RPE) degeneration. The project, which commenced August 1, 2025 and concludes July 31, 2027, focuses on developing innovative interventions to address...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded New York University School of Medicine a $673,747 Vision Research project grant (CFDA 93.867) commencing June 1, 2025, and concluding May 31, 2030, to develop advanced optical imaging technology for early detection of age-related macular degeneration (AMD). The research focuses on advancing visible-to-near-infrared spanning optical coherence tomography (OCT) to achieve half-micron axial resolution for retinal imaging,...
- Federal Project Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded the University of Maryland, Baltimore $249,000 on September 30, 2025, for a three-year research project (completion date: August 31, 2028) investigating retinal pigment epithelium (RPE) cell dynamics in the living human eye. The primary deliverable is the development and validation of a translational fluorescence lifetime imaging approach to characterize intracellular...
- This Project Grant award, totaling $620,149, was provided by the National Eye Institute under the Vision Research federal grant program (CFDA 93.867) with a performance period from April 1, 2025 to March 31, 2030. The University of Iowa will conduct base editing and prime editing of risk loci in human cells, including iPSC-derived retinal pigment epithelium, retina, and choroid, as well as donor retinal and choroidal explant cultures. The goal is to address fundamental scientific questions...
- Federal Grant Award Summary Oregon Health & Science University received a $598,108 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025, with completion targeted for April 30, 2030. The grant funds a multidisciplinary program to develop innovative ophthalmic imaging technologies and objective biomarkers for assessing cone photoreceptor function and integrity. The primary deliverables include next-generation...
- Federal Project Grant Award Summary Award Details: The National Eye Institute (National Institutes of Health) awarded a Vision Research federal grant (CFDA 93.867) to the University of California, San Diego totaling $638,625 for the period August 1, 2025 through July 31, 2028. This project grant funds research into the mechanisms underlying drusen formation in age-related macular degeneration (AMD), a leading cause of blindness affecting approximately 196 million people globally. Research...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded $830,024 to the University of Colorado-Denver for a two-year project (September 1, 2025–August 31, 2027) investigating the mechanisms of retinal cell fate specification during retinal development. The research focuses on elucidating how the Notch signaling pathway regulates competence and fate choice decisions in retinal progenitor cells, which differentiate into seven major...
- This Project Grant award, provided by the National Eye Institute (CFDA 93.867 - Vision Research), is supporting research at The University of Iowa to enable the production of autologous (patient-derived) cell therapies for treating inherited retinal degenerative blindness. The $618,600 award, effective from March 1, 2025 to February 28, 2030, aims to address key challenges in the manufacturing of these personalized cell therapies, such as assessing retinal differentiation capacity and...
- Federal Grant Award Summary The National Eye Institute (NEI) Vision Research program (CFDA 93.867) awarded $1,813,621 to The Research Foundation for the State University of New York effective August 1, 2025, through March 31, 2029, to conduct a prospective metabolomic analysis examining the relationship between nutritional biomarkers and age-related macular degeneration (AMD) in postmenopausal women. The project leverages the Carotenoids in Age-Related Eye Disease Study (CAREDS), an ancillary...
- Federal Project Grant Award Summary The University of Rochester received a $658,889 project grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective July 1, 2025 through April 30, 2029. This award supports research investigating the pathogenic role of secretory phospholipase A2-IIA (PLA2G2A/SPLA2-IIA), a pro-inflammatory enzyme, in age-related macular degeneration (AMD), a leading cause of adult blindness. The research will deliver scientific...
Federal Grant Award Summary The National Eye Institute's Vision Research program (CFDA 93.867) awarded a $860,190 Project Grant to Oregon Health & Science University effective February 6, 2026, through January 31, 2031. This research initiative focuses on developing a scalable allogeneic retinal pigment epithelial (RPE) cell-based therapy designed to address age-related macular degeneration (AMD) in elderly populations. The project aims to advance hypoimmune RPE cell transplant technology in nonhuman primate models to demonstrate survival, engraftment, and immune evasion without requiring systemic immunosuppression—a critical advancement that would eliminate safety concerns associated with long-term immunosuppressive regimens currently required in clinical trials. The research addresses a significant gap in current AMD treatment approaches by developing an alternative to autologous cell therapies, which, while effective, present substantial logistical and cost barriers to broad implementation. By establishing a more accessible, efficient, and cost-effective allogeneic cell therapy platform, this project aims to generate preclinical evidence in nonhuman primates to support future clinical translation and ultimately improve access to RPE transplantation therapy for millions of individuals experiencing progressive vision loss from advanced dry AMD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $860.2k | 2/6/26 |